drugset
drugset / Trial / NCT00050154

Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

NCT00050154 ↗

Phase 2 Completed 82 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the hematological response rate, as well as other parameters of efficacy and safety induced by tipifarnib in patients with high-risk myelodysplastic syndrome (MDS). Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI). It blocks proteins that make cancer cells grow.

Timeline

Start
2002-07
Primary completion
—
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule 300 mg Oral

Indications

myelodysplastic syndrome